Fig. 4: Downregulation of Fkbp5 improves left ventricular functions.
From: DNA methylation predicts adverse outcomes of coronary artery disease
a Relative Fkbp5 mRNA expression in heart tissue of wild-type and Fkbp5−/− mice (n = 3 for each group, N = 3 experiments, *P = 0.018, **P = 0.007). b Representative echocardiogram images of wild-type and Fkbp5−/− mice with sham or myocardial ischemia-reperfusion operation. c Left ventricular ejection fraction in wild-type and Fkbp5−/− mice with sham or myocardial ischemia-reperfusion operation (nWT-sham = 7, nKO-sham = 7, nWT-MI/R = 10, nKO-MI/R = 8, ****P < 0.0001). d Left ventricular fractional shortening in wild-type and Fkbp5−/− mice with sham or myocardial ischemia-reperfusion operation (nWT-sham = 7, nKO-sham = 7, nWT-MI/R = 10, nKO-MI/R = 8, ***P = 0.0002, **P = 0.008). e Representative images of heart sections by TTC/Evans Blue staining depicting the infarcted area. f, g Cardiac injury was evaluated by the ratio of infarct size (INF) to area at risk (AAR) (nWT-MI/R = 4, nKO-MI/R = 4, *P = 0.029). h Platelet-to-lymphocyte ratio of wild-type and Fkbp5−/− mice with sham or myocardial ischemia-reperfusion operation (nWT-sham = 6, nKO-sham = 6, nWT-MI/R = 6, nKO-MI/R = 5, ***P = 0.0003, *P = 0.039). WT wild type, KO knockout, LVEF left ventricular ejection fraction, LVFS left ventricular fractional shortening, AAR: area at risk, INF infarct size, LV left ventricular, PLR platelet-lymphocyte ratio. Data are presented by mean ± SD for each group. Statistical significance was performed by two-way ANOVA with Šídák’s test for multiple comparisons. ns no significance, *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.0001. Source data were provided as a Source Data file.
